Allylprodine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Allylprodine
Allylprodine.svg
Clinical data
ATC code
  • none
Legal status
Legal status
Identifiers
Synonyms Allylprodine
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
Formula C18H25NO2
Molar mass 287.397 g/mol
3D model (Jmol)
 NYesY (what is this?)  (verify)

Allylprodine[1] is an opioid analgesic that is an analog of prodine. It was discovered in by Hoffman-La Roche in 1957 during research into the related drug pethidine. Derivatives were tested to prove the theory that phenolic & non-phenolic opioids bind at different sites of the opiate receptor.

Allylprodine is more potent as an analgesic than similar drugs such as α-prodine, and the 3R,4S-isomer is 23 times more potent than morphine, due to the allyl group binding to an additional amino acid target in the binding site on the μ-opioid receptor. It is also stereoselective, with one isomer being much more active.[2][3] When modeled in three dimensions, the alkene overlays the alkenes found in 14-cinnamoyloxycodeinone and in 14-allyloxycodeinone, re-enforcing the presence of an interaction of the alkene.[citation needed]

Allylprodine produces similar effects to other opioids, such as analgesia and sedation, along with side effects such as nausea, itching, vomiting and respiratory depression which may be harmful or fatal.

Legal status[edit]

Allylprodine is regulated in most countries as is morphine, including being in Schedule I of the US Controlled Substances Act 1970 as a Narcotic with ACSCN 9602 and a 2014 annual aggregate manufacturing quota of 2 grammes.[4]

Australia[edit]

Allylprodine is considered a Schedule 9 prohibited substance in Australia under the Poisons Standard (February 2017).[5] A Schedule 9 substance is a substance which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities.[5]


References[edit]

  1. ^ U.S. Patent 2,798,073 - PIPERIDINE DERIVATIVES AND PREPARATION
  2. ^ Portoghese, P. S.; Shefter, E (1976). "Stereochemical studies on medicinal agents. 19. X-ray crystal structures of two (+/-)-allylprodine diastereomers. The role of the allyl group in conferring high stereoselectivity and potency at analgetic receptors". Journal of Medicinal Chemistry. 19 (1): 55–7. doi:10.1021/jm00223a012. PMID 1246054. 
  3. ^ Portoghese, P. S.; Alreja, B. D.; Larson, D. L. (1981). "Allylprodine analogues as receptor probes. Evidence that phenolic and nonphenolic ligands interact with different subsites on identical opioid receptors". Journal of Medicinal Chemistry. 24 (7): 782–7. doi:10.1021/jm00139a004. PMID 6268787. 
  4. ^ http://www.deadiversion.usdoj.gov/fed_regs/quotas/2014/fr0825.htm
  5. ^ a b Poisons Standard October 2015 https://www.legislation.gov.au/Details/F2017L00057